SAGE Therapeutics’ Strategic Collaboration with Shionogi
On June 13, SAGE Therapeutics (SAGE) announced a strategic collaboration with Shionogi & Company for the development and commercialization of the drug SAGE-217. Let’s take a look at the details of the collaboration.